LinkedIn IconTwitter Icon

28-29 November 2018, Berlin

Speakers

Expand/Collapse

Craig Blanchette
Senior Scientist
Genentech

Day Two

Thursday 29 November

10.00 | Panel Discussion: Investigating Biomarkers to Predict Responses to Immunotherapy: Which Factors in the Biological Profile of the Patient Should We Assess?

09.00 | Developing a Personalized Immune Monitoring Program: Applications to Personalised Cancer Vaccine (PCV) Therapeutics

Mathieu Blery
Senior Director, Translational Immunology
Innate Pharma

Day Two

Thursday 29 November

14.00 | Next Generation Immunotherapies: Targeting Innate Lymphocytes and Tumour Microenvironment

Jannie Borst
Head, Division of Tumor Biology and Immunology
Netherlands Cancer Institute

Day Two

Thursday 29 November

16.30 | Chair’s Closing Remarks

11.30 | Enticing Cytotoxic T Cells to Attack Cancer: The Importance of CD4 T Cell Help

08.50 | Chair's Opening Remarks

Tanja de Gruijl
Professor, Translational Tumor Immunology & Head of Immunotherapy Lab
VU University Medical Center

Day One

Wednesday 28 November

13.30 | Therapeutic Modulation of the Microenvironment of Tumour-Draining Lymph Nodes Through Local Administration of TLR Agonists or Immune Checkpoint Inhibitors

Wolf-Dietrich Doecke
Director, Biomarker Strategist
Bayer

Day Two

Thursday 29 November

10.00 | Panel Discussion: Investigating Biomarkers to Predict Responses to Immunotherapy: Which Factors in the Biological Profile of the Patient Should We Assess?

Walter Ferlin
Head of Exploratory Science & Translational Medicine
NovImmune

Day Two

Thursday 29 November

16.00 | Panel Discussion: Contrasting Therapeutic Modalities in Immuno- Oncology

14.30 | Gaining Insights into the Development of CD47-Targeted Bispecific Antibodies

Tina Furebring
Vice President, Research & Development, Research
Alligator Bioscience

Day One

Wednesday 28 November

14.30 | Bispecific Concepts for Tumor Localization of Immuno-Oncology Antibodies

Laura Helming
Director, Scientific Site Head, Immuno-Oncology
Merck KGaA

Day Two

Thursday 29 November

13.30 | Enhancing Anti-Tumour Activity by Targeting the Tumour Microenvironment

Marlon Hinner
Group Leader, In Vitro Display
Roche

Day Two

Thursday 29 November

16.00 | Panel Discussion: Contrasting Therapeutic Modalities in Immuno- Oncology

Christian Hosius
Regional Clinical Director European Clinical Development, Oncology
Merck Sharpe & Dohme

Day Two

Thursday 29 November

10.00 | Panel Discussion: Investigating Biomarkers to Predict Responses to Immunotherapy: Which Factors in the Biological Profile of the Patient Should We Assess?

09.30 | Checkpoint Inhibitor Keytruda® as a Therapeutic Strategy in Oncology

Zoë Johnson
CSO
iOnctura

Day One

Wednesday 28 November

16.00 | PI3Kδ: A New Era in Immuno-Oncology

Reece Marillier
Research Scientists, In Vivo Pharmacology
iTeos Therapeutics

Day One

Wednesday 28 November

11.15 | Preclinical Mouse Models to Support the Rapid Development of Innovative Immuno-Oncology Therapeutics

Nicolo Rigamonti
Biology Lead & Project Leader, Cancer Immunology
Molecular Partners

Day Two

Thursday 29 November

16.00 | Panel Discussion: Contrasting Therapeutic Modalities in Immuno- Oncology

15.30 | Fibroblast Activation Protein (FAP)-Selective Delivery of CD40 Agonistic DARPin® Protein for Tumour-Localized Immune Activation

Kris Sachsenmeier
Associate Director, Translational Science, IMED Oncology
AstraZeneca

Day One

Wednesday 28 November

09.00 | Keynote – Adenosine-mediated Immunosuppression: Escape From First Generation Checkpoint Inhibitors

Zhen Su
Senior Vice President & Chief Medical Officer
Merck KGaA

Day One

Wednesday 28 November

16.30 | Chair’s Closing Remarks

08.30 | Keynote – Evaluating How the Immuno-Oncology Therapies Have Changed the Standard of Care in Oncology & What This Means for the Field & Patients

08.20 | Chairs Opening Remarks

Tim Sullivan
Vice President, Business Development
Vice President, Business Development

Day Two

Thursday 29 November

12.00 | Discovery & Development of AB154, a Novel Antibody Targeting TIGIT

Frederic Triebel
CSO & CMO
Immutep

Day One

Wednesday 28 November

14.00 | Two ACTive Immunotherapies (TACTI): Results of a Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg Or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrolizumab

Janet Peper
Biological Lead, Immuno-Oncology & Team Leader, Preclinical Assay Development
Pieris Pharmaceuticals

Day One

Wednesday 28 November

15.30 | Tumor-Localized T Cell Costimulation Using Antibody-Anticalin® Fusion Proteins: From Flexible Design to Proof of Concept & Beyond - PRS-344, a PD-L1/4-1BB Bispecific

Erin Newburn
Associate Director, Field Applications Scientist
Personalis

Day One

Wednesday 28 November

09.30 | Enabling Multidimensional Biomarker Discovery: Interrogating the Tumor, its Microenvironment, and Neoantigens with ACE ImmunoID

Roberto Spada
Market Development Specialist
Fluidigm

Day Two

Thursday 29 November

10.30 | Advancing Breakthroughs in Immuno-Oncology Research